Literature DB >> 2468456

Penetration of fleroxacin into prostatic secretion and prostatic adenoma tissue.

F Kees1, K G Naber, H Schumacher, H Grobecker.   

Abstract

In 12 elderly patients, plasma, prostatic secretion and adenoma tissue concentrations of fleroxacin were determined 1-4 h following oral administration of 400 mg. The plasma concentrations ranged between 0.4 and 5.5 micrograms/ml (median 3.7 micrograms/ml), the mean tissue concentrations were slightly higher. The concentrations in prostatic secretion were about one third of the simultaneous plasma concentrations. High concentrations of the concomitantly administered ioxithalamic acid in prostatic secretion are considered as indicative of urinary contamination, and in this case the fleroxacin concentrations are questionable. The drug levels in prostatic adenoma tissue were similar to the concomitantly measured plasma levels.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2468456     DOI: 10.1159/000238605

Source DB:  PubMed          Journal:  Chemotherapy        ISSN: 0009-3157            Impact factor:   2.544


  6 in total

Review 1.  Fleroxacin clinical pharmacokinetics.

Authors:  A E Stuck; D K Kim; F J Frey
Journal:  Clin Pharmacokinet       Date:  1992-02       Impact factor: 6.447

Review 2.  Quinolones as a Potential Drug in Genitourinary Cancer Treatment-A Literature Review.

Authors:  Tomasz Kloskowski; Sylwia Frąckowiak; Jan Adamowicz; Kamil Szeliski; Marta Rasmus; Tomasz Drewa; Marta Pokrywczyńska
Journal:  Front Oncol       Date:  2022-06-08       Impact factor: 5.738

3.  Pharmacokinetics of [18F]fleroxacin in patients with acute exacerbations of chronic bronchitis and complicated urinary tract infection studied by positron emission tomography.

Authors:  A J Fischman; E Livni; J W Babich; N M Alpert; A Bonab; S Chodosh; F McGovern; P Kamitsuka; Y Y Liu; R Cleeland; B L Prosser; J A Correia; R H Rubin
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

4.  Pharmacokinetics of [18F]fleroxacin in healthy human subjects studied by using positron emission tomography.

Authors:  A J Fischman; E Livni; J Babich; N M Alpert; Y Y Liu; E Thom; R Cleeland; B L Prosser; J A Correia; H W Strauss
Journal:  Antimicrob Agents Chemother       Date:  1993-10       Impact factor: 5.191

Review 5.  Fleroxacin. A review of its pharmacology and therapeutic efficacy in various infections.

Authors:  J A Balfour; P A Todd; D H Peters
Journal:  Drugs       Date:  1995-05       Impact factor: 9.546

6.  Pharmacokinetics of 18F-labeled fleroxacin in rabbits with Escherichia coli infections, studied with positron emission tomography.

Authors:  A J Fischman; E Livni; J Babich; N M Alpert; Y Y Liu; E Thom; R Cleeland; B L Prosser; R J Callahan; J A Correia
Journal:  Antimicrob Agents Chemother       Date:  1992-10       Impact factor: 5.191

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.